Launch Tracking · White Paper · June 2026
Blind Spots in Launch Tracking
What five launch teams revealed
Five scenarios. Five blind spots. One structural failure underneath all of them.
What you'll learn
How chart-level pharma launch tracking data revealed a competitor's archetype footprint that aggregate share data missed, and why it changed the field-force narrative before launch.
Why a planned safety-reassurance campaign would have introduced the fear it was designed to dispel, and how three HCP research instruments converged on the actual patient barrier.
How a message-sequencing analysis resolved a months-long internal debate about what to lead with, and recovered physician prescribing intent in one cycle.
Why weekly HCP fielding caught a PCP vs. specialist divergence at Month 5 that monthly launch tracking would have caught at Month 9.
About This Research
The five scenarios in this white paper are drawn from real ZoomRx Launch Tracking engagements across therapy areas and company scales, from a first-launch biotech to a top-ten pharma.
Each documents a specific blind spot, the instrument that surfaced it, and the action taken while the launch window was still open.
These are not hypothetical scenarios. They are the questions pharma launches actually ask, and what it took to answer them in time.
About ZoomRx Launch Tracking
ZoomRx serves 19 of the top 20 global biopharma companies.
ZoomRx Launch Tracking is a single integrated platform (continuous HCP panels, patient chart modules, competitive promotion tracking, pre-launch benchmarks, and qualitative layers) configured to the specific question a launch needs to answer.